BMO Capital Markets Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00

Replimune Group (NASDAQ:REPL) had its target price raised by stock analysts at BMO Capital Markets from $14.00 to $18.00 in a report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price target indicates a potential upside of 20.56% from the stock’s current price.

Several other research analysts have also commented on REPL. Roth Mkm assumed coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Trading Up 35.1 %

Shares of REPL stock opened at $14.93 on Friday. The company has a 50-day moving average of $11.59 and a two-hundred day moving average of $9.72. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The firm has a market cap of $1.02 billion, a PE ratio of -4.90 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. On average, analysts predict that Replimune Group will post -3.02 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC raised its holdings in Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after purchasing an additional 98,791 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after acquiring an additional 217,308 shares during the period. State Street Corp increased its holdings in shares of Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after acquiring an additional 1,182,181 shares during the period. Parkman Healthcare Partners LLC increased its holdings in shares of Replimune Group by 45.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after acquiring an additional 238,747 shares during the period. Finally, Arizona PSPRS Trust acquired a new position in shares of Replimune Group in the 3rd quarter valued at $834,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.